WO2002087504A2 - Methodes d'inhibition de la proliferation des cellules tumorales - Google Patents

Methodes d'inhibition de la proliferation des cellules tumorales Download PDF

Info

Publication number
WO2002087504A2
WO2002087504A2 PCT/US2002/013502 US0213502W WO02087504A2 WO 2002087504 A2 WO2002087504 A2 WO 2002087504A2 US 0213502 W US0213502 W US 0213502W WO 02087504 A2 WO02087504 A2 WO 02087504A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
tumor
sequence
active agent
adenocarcinoma
Prior art date
Application number
PCT/US2002/013502
Other languages
English (en)
Other versions
WO2002087504A9 (fr
Inventor
Kathleen E. Rodgers
Gere S. Dizerega
Original Assignee
University Of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Southern California filed Critical University Of Southern California
Priority to AU2002308522A priority Critical patent/AU2002308522A1/en
Publication of WO2002087504A2 publication Critical patent/WO2002087504A2/fr
Publication of WO2002087504A9 publication Critical patent/WO2002087504A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Definitions

  • This present invention relates to compositions and methods useful for the inhibition of tumor cell proliferation.
  • the present invention provides methods for inhibiting tumor cell proliferation by administering to a patient in need thereof an amount effective of angiotensinogen, angiotensin I (Al), Al analogues, Al fragments and analogues thereof, angiotensin II (All),
  • the tumor comprises an adenocarcinoma.
  • the tumor comprises an adenocarcinoma of ovarian, endometrial, uterine, or breast origin.
  • angiotensin converting enzyme inhibitors or "ACE inhibitors” includes any compound that inhibits the conversion of the decapeptide angiotensin I to angiotensin II, and include but are not limited to alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzazepril, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, converstatin, delapril, delapril-diacid, enalapril, enalaprilat, enalkiren, enapril, epicaptopril, foroxymithine, fosfenopril, fosen
  • active agents refers to the group of compounds comprising angiotensinogen, angiotensin I (Al), Al analogues, Al fragments and analogues thereof, angiotensin II (All), All analogues, All fragments or analogues thereof or All AT 2 type 2 receptor agonists, either alone, combined, or in further combination with other compounds, for inhibiting tumor cell proliferation.
  • tumor includes refers to tumor types including but not limited to carcinomas, which as used herein refers to tumors originating in the epithelial cells of an organ.
  • the tumor type is an adenocarcinoma, which as used herein refers to a subclass of carcinomas that originate in a glandular portion of an organ.
  • the organ in which the adenocarcinoma originates is selected from the group consisting of ovarian, endometrial, uterine, and breast tissues, most preferably from endometrial or breast tissue.
  • the active agents may be more active inhibiting proliferation of hormone-dependent tumors, including but not limited to those of ovarian, endometrial, uterine, and breast origin.
  • the term "amount effective to inhibit tumor cell proliferation” is taken to mean an appropriate quantity of one or more active agents, that when administered to a subject in need thereof, results in a slowing or stopping of the rate of progression of tumor cell growth, and/or that decreases the size of a pre-existing tumor in a subject.
  • the active agents thus act as chemotherapeutic agents for inhibiting tumor cell proliferation and tumor growth in a patient in need thereof, and thus further chemotherapeutic agents are not needed.
  • angiotensin The biological formation of angiotensin is initiated by the action of renin on the plasma substrate angiotensinogen (Circulation Research 60:786-790 (1987); Clouston et al., Genomics 2:240-248 (1988); Kageyama et al., Biochemistry 23:3603-3609; Ohkubo et al., Proc. Natl. Acad. Sci. 80:2196-2200 (1983)); all references hereby incorporated in their entirety).
  • the substance so formed is a decapeptide called angiotensin I (Al) which is converted to All by the converting enzyme angiotensinase which removes the C-terminal His-Leu residues from Al, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe- His-Leu [SEQ ID NO:37]. All is a known pressor agent and is commercially available.
  • angiotensinogen angiotensin I (Al), Al analogues, Al fragments and analogues thereof, angiotensin II (All), All analogues, All fragments or analogues thereof; All AT 2 type 2 receptor agonists are effective in accelerating wound healing, the proliferation of certain cell types, and are effective when used as adjuncts to chemotherapy or radiation therapy to treat patients in need of such treatment. See, for example, co-pending U.S. Patent Application Serial Nos.
  • AII(l-7) activity on a particular cell type cannot be predicted based solely on the effect of All on the same cell type.
  • AII(l-7) often opposes the actions of AIL (See, for example, Ferrario et al., Hypertension 30:535-541 (1997))
  • AII(l-7) (SEQ ID NO:4) has been shown to inhibit smooth muscle cell proliferation, and to reduce smooth muscle cell growth after vascular injury (Strawn et al., Hypertension 33:207-211 (1999)).
  • A(II) in contrast, is known to increase proliferation of smooth muscle cells (Mueck, et al., Int. J. Clin. Pharmacol. Ther., 37(7):365-6 (1999)).
  • captopril has been shown to have antitumor activity in a xenograft mouse model of human renal cell carcinoma, although proliferation of renal carcinoma cells in vitro was not inhibited by captopril (Hii et al., Br. J. Cancer 77(6):880-83 (1998)). Similar in vitro studies have demonstrated that captopril can inhibit proliferation of human mammary ductal carcinoma cells (Small Jr., et al., Breast Cancer Res. Treat., 44(3):217-24 (1997)) as well as hamster pancreatic duct carcinoma cells (Reddy, et al., Proc. Soc. Exp. Biol. Med., 210(3):221-6 (1995)).
  • a peptide agonist selective for the AT2 receptor (All has 100 times higher affinity for AT2 than ATI) is p-aminophenylalanine6-AII ["(p-NH 2 -Phe)6-AII)"], Asp-Arg-Val-Tyr-Ile- Xaa-Pro-Phe [SEQ ID NO.36] wherein Xaa is p-NH 2 -Phe (Speth and Kim, BBRC 169:997- 1006 (1990).
  • a preferred class of AT2 agonists for use in accordance with the present invention comprises All analogues or active fragments thereof having p-NH 2 -Phe in a position corresponding to a position 6 of AIL
  • various nonpeptidic agents e.g., peptidomimetics
  • having the requisite AT2 agonist activity are further contemplated for use in accordance with the present invention.
  • the active agents of particular interest in accordance with the present invention comprise a sequence of at least three contiguous amino acids of groups R'-R 8 in the sequence of general formula I
  • R 2 is is selected from the group consisting of Arg, Lys, Ala, Citron, Orn, Ser(Ac), Sar, D-Arg and D-Lys,
  • R 3 is selected from the group consisting of Val, Ala, Leu, norLeu, He, Gly, Lys, Pro, HydroxyPro, Aib, Acpc and Tyr;
  • R 4 is selected from the group consisting of Tyr, Tyr(PO ) 2 , Thr, Ser, homoSer, azaTyr, and Ala;
  • R 5 is selected from the group consisting of He, Ala, Leu, norLeu, Val and Gly;
  • R 6 is selected from the group consisting of His, Arg or 6-NH 2 -Phe;
  • R 7 is selected from the group consisting of Pro or Ala
  • R 8 is selected from the group consisting of Phe, Phe(Br), He and Tyr, excluding sequences including R 4 as a terminal Tyr group.
  • the active agents comprise a sequence of at least four, five, six, or seven contiguous amino acids of groups R -R in the sequence of general formula I.
  • the active agents consist of a sequence of at least four, five, six, or seven contiguous amino acids of groups R -R in the sequence of general formula I.
  • R and R are Asp- Arg, Asp-Lys, Glu-Arg and Glu-Lys.
  • Particularly preferred embodiments of this class comprise the following amino acid sequences: All [SEQ ID NO:l]; ALII or AII(2-8), Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ JD NO:2]; AII(3-8), also known as desl-AIII or ALV, Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:3]; AII(l-7), Asp-Arg-Val-Tyr-Ile-His-Pro [SEQ ID NO:4]; AII(2-7), Arg-Val-Tyr-Ile-His-Pro [SEQ ID NO:5]; AII(3-7), Val-Tyr-Ile-His-Pro [SEQ ID NO:6]; AII(5-8), Ile-His-Pro-Phe [SEQ ID NO:
  • Arg-norLeu-Tyr-Ile-His- Pro-Phe [SEQ ID NO: 12] and Arg-Val-Tyr-norLeu-His-Pro-Phe [SEQ ED NO: 13].
  • Still another preferred embodiment encompassed within the scope of the invention is a peptide having the sequence Asp-Arg-Pro-Tyr-Ile-His-Pro-Phe [SEQ ID NO:31].
  • AII(4-8), Tyr-Ile- His-Pro-Phe [SEQ ID NO: 15] was also tested and found not to be effective.
  • R is selected from the group consisting of H, Arg, Lys, Ala, Orn, Citron, Ser(Ac), Sar, D-Arg and D-Lys;
  • R 3 is selected from the group consisting of Val, Ala, Leu, norLeu, He, Gly, Pro, Hydroxy-Pro, Aib, Acpc and Tyr;
  • R 4 is selected from the group consisting of Tyr, Tyr(PO ) 2 , Thr, Ser, homoSer, azaTyr, and Ala;
  • R 5 is selected from the group consisting of He, Ala, Leu, norLeu, Val and
  • R 6 is His, Arg or 6-NH 2 -Phe
  • R 7 is Pro or Ala
  • R is selected from the group consisting of Phe, Phe(Br), He and Tyr.
  • a particularly preferred subclass of the compounds of general formula II has the formula
  • R 2 -R 3 -Tyr-R 5 -His-Pro-Phe (SEQ ED NO: 16] wherein R 2 , R 3 and R 5 are as previously defined.
  • Particularly preferred compounds include peptides having the structures Arg-Val-Tyr-Gly-His-Pro-Phe [SEQ ID NO: 17] and Arg-Val-Tyr-Ala-His-Pro-Phe [SEQ ID NO: 18].
  • the fragment AII(4-8) was ineffective in repeated tests; this is believed to be due to the exposed tyrosine on the N-terminus.
  • the active agents comprise an amino acid sequence selected from the group consisting of any one of SEQ ID NOS: 1-51. In an further embodiment, the active agent does not consist of All (SEQ ID NO:l). In a further embodiment, the active agent comprises the amino acid sequence of SEQ ED NO:4 (AII(1- 7)). In a further embodiment, the active agent consists of the amino acid sequence of any of SEQ ID NOS: 1-51. In a further preferred embodiment, the active agent consists of the amino acid of SEQ ED NO:4.
  • R 2 Appropriate side chains on the amino acid in position R 2 may contribute to affinity of the compounds for target receptors and/or play an important role in the conformation of the peptide. For this reason, Arg and Lys are particularly preferred as R 2 .
  • R 2 may be H, Ala, Orn, Citron, Ser(Ac), Sar, D-Arg, or D-Lys.
  • R may be involved in the formation of linear or nonlinear hydrogen bonds with R 5 (in the gamma turn model) or R 6 (in the beta turn model).
  • R 3 would also participate in the first turn in a beta antiparallel structure (which has also been proposed as a possible structure).
  • R 3 may suitably be selected from Lys, Val, Ala, Leu, norLeu, He, Gly, Pro, Hydroxy-Pro, Aib, Acpc and Tyr.
  • R 4 is preferably selected from Tyr, Thr, Tyr (PO ) 2 , homoSer, Ser and azaTyr.
  • Tyr is particularly preferred as it may form a hydrogen bond with the receptor site capable of accepting a hydrogen from the phenolic hydroxyl (Regoli, et al. (1974), supra). It has also been found that R 4 can be Ala.
  • an amino acid with a ⁇ aliphatic or alicyclic chain is particularly preferred
  • Gly is suitable in position R 5 , it is preferred that the amino acid in this position be selected from He, Ala, Leu, norLeu, and Val.
  • R 7 7 the orientation of R .
  • R should be Pro or Ala in order to provide the most desirable orientation of R 8 .
  • both a hydrophobic ring and an anionic carboxyl terminal appear to be particularly useful in binding of the analogues of interest to receptors; therefore, Tyr, He, Phe(Br), and especially Phe are preferred for purposes of the present invention.
  • polypeptides of the instant invention may be synthesized by any conventional method, including, but not limited to, those set forth in J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, 2nd ed., Pierce Chemical Co., Rockford, 111. (1984) and J. Meienhofer, Hormonal Proteins and Peptides, Vol. 2, Academic Press, New York, (1973) for solid phase synthesis and E. Schroder and K. Lubke, The Peptides, Vol. 1, Academic Press, New York, (1965) for solution synthesis.
  • the disclosures of the foregoing treatises are incorporated by reference herein. In general, these methods involve the sequential addition of protected amino acids to a growing peptide chain (U.S. Patent No.
  • peptides are synthesized according to standard solid-phase methodologies, such as may be performed on an Applied Biosystems Model 430A peptide synthesizer (Applied Biosystems, Foster City, Calif), according to manufacturer's instructions. Other methods of synthesizing peptides or peptidomimetics, either by solid phase methodologies or in liquid phase, are well known to those skilled in the art.
  • the peptides can be produced by standard molecular biological techniques.
  • compositions comprising an effective amount of one or more of the active agents of the present invention to inhibit tumor cell proliferation, in combination with a pharmaceutically acceptable carrier.
  • of the present invention provides for a method of inhibiting tumor cell proliferation by contacting tumor cells with an amount effective of one or more of the active agents of the present invention, or pharmaceutical compositions thereof, such that tumor cell proliferation is inhibited.
  • the present invention provides methods for the inhibition of tumor cell proliferation by administering to a patient in need thereof an amount effective to inhibit tumor cell proliferation of one or more of the active agents or pharmaceutical compositions of the invention, either alone or in further combination with other compounds and methods effective for inhibiting tumor cell proliferation.
  • the tumor comprises a carcinoma, more preferably an adenocarcinoma.
  • the organ in which the adenocarcinoma originates is selected from the group consisting of ovarian, endometrial, uterine, and breast tissues, most preferably from endometrial or breast tissue.
  • the active agents may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions), and may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as stabilizers, wetting agents, emulsifiers, preservatives, co- solvents, suspending agents, viscosity enhancing agents, ionic strength and osmolality adjustors and other excipients in addition to buffering agents.
  • conventional adjuvants such as stabilizers, wetting agents, emulsifiers, preservatives, co- solvents, suspending agents, viscosity enhancing agents, ionic strength and osmolality adjustors and other excipients in addition to buffering agents.
  • Suitable water soluble preservatives which may be employed in the drug delivery vehicle include sodium bisulfite, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric borate, parabens, benzyl alcohol, phenylethanol or antioxidants such as Vitamin E and tocopherol and chelators such as EDTA and EGTA. These agents may be present, generally, in amounts of about 0.001% to about 5% by weight and, preferably, in the amount of about 0.01 to about 2% by weight.
  • the active agents are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration.
  • the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration.
  • the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal solutions, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers.
  • Other adjuvants and modes of administration are well known in the pharmaceutical art.
  • the carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.
  • Suitable delivery vehicles include, but are not limited to, the following: microcapsules or microspheres; liposomes and other lipid-based release systems; crystalloid and viscous instillates; absorbable and/or biodegradable mechanical barriers; and polymeric delivery materials, such as polyethylene oxide/polypropylene oxide block copolymers (e.g. poloxamers), poly-orthoesters, cross-linked polyvinyl alcohol, polyanhydrides, polymethacrylate and polymethacryladmide hydrogels, anionic carbohydrate polymers, etc.
  • Useful delivery systems are well known in the art and are described in, e.g., U.S. Pat. No. 4,937,254, the entire disclosure of which is hereby incorporated by reference.
  • the active agents may be administered by any suitable route, including local delivery, parentally, transdermally, or dermally in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles.
  • parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, intratendinous, intraspinal, intracranial, intrathoracic, infusion techniques or intraperitoneally.
  • Local delivery of the active agents of the invention can be by a variety of techniques that administer the agent at or near the site of neoplastic growth.
  • site-specific or targeted local delivery techniques are not intended to be limiting but to be illustrative of the techniques available.
  • Examples include local delivery catheters, such as an infusion catheter, an indwelling catheter, or a needle catheter, stets, synthetic grafts, adventitial wraps, shunts and stents or other implantable devices, site specific carriers, direct injection, or direct applications. (U.S. Patent 5,981,568, incorporated by reference herein in its entirety.)
  • Local delivery by an implant describes the surgical placement of a matrix that contains the active agent into the tumor or immediate surrounding area.
  • the implanted matrix can release the active agent by diffusion, chemical reaction, or solvent activators. See, for example, Lange, Science, 249, 1527 (1990).
  • Another example is a delivery system in which a polymer that contains the active agent is injected into the area of the tumor in liquid form. The polymer then solidifies or cures to form an implant that is retained in situ. This technique is described in PCT WO 90/03768 (Donn, Apr. 19, 1990), the disclosure of which is incorporated by reference herein.
  • the active agents may be formulated as is known in the art for direct application to a target area.
  • Conventional forms for this purpose include wound dressings, coated bandages or other polymer coverings, ointments, lotions, pastes, jellies, sprays, and aerosols.
  • the percent by weight of the active agent of the invention present in a topical formulation will depend on various factors, but generally will be from 0.005% to 95% of the total weight of the formulation, and typically 1-25% by weight.
  • the dosage regimen for treating or preventing tumor cell growth with the active agents is based on a variety of factors, including the age, weight, sex, medical condition of the individual, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined by a physician. Dosage levels of the order of between 0.1 ng/kg and 10 mg/kg of the active agents per body weight are useful for all methods of use disclosed herein.
  • an amount effective of the active agents or pharmaceutical compositions comprising the active agents to inhibit tumor cell proliferation is administered to a patient in need of such treatment as soon as possible following diagnosis of a tumorigenic growth.
  • compositions that comprise an amount effective to treat or prevent tumor cell proliferation of one or more of the active agents of the invention alone or in combination with other anti-tumor agents, including but not limited to angiotensin converting enzyme inhibitors and angiogenesis inhibitors.
  • the present invention by providing methods for treating or preventing tumor cell proliferation is broadly useful to treat or inhibit tumor cell growth. It will be recognized that the active agents and dosage forms (both free and sustained release) of the invention are not restricted in use for therapy following other methods such as surgical excision. Thus, other aspects of the invention include therapeutic conjugates, dosage forms, and protocols useful in sustained therapeutic intervention for reducing, delaying, or eliminating further tumor cell growth.
  • Test Article AII(l-7), 0.1 ng/ml - lO ⁇ g/ml (1.1 x 10 " 1'0 ⁇ to 1.1 x 10
  • Tumor Cell Preparation Primary and metastatic tumors obtained from the Department of Obstetrics and Gynecology Pathology Section and the Surgical Pathology Division of Los Angeles County/University of Southern California were minced into pieces less than 2 mm in diameter in the presence of RPMI-1640 (Gibco, Grand Island, NTY) containing 15% heat- inactivated fetal calf serum. Each gram of tumor tissue was treated with 10-20 mL of enzyme medium, consisting of Hanks' balanced salt solution with 0.03% DNAse (500 Kunitz units/mL; Sigma Chemical Co., St. Louis, MO) and 0.14% collagenase type I (Sigma). Tumor fragments were stirred for 90 minutes at 37°C in the presence of 5% CO 2 .
  • enzyme medium consisting of Hanks' balanced salt solution with 0.03% DNAse (500 Kunitz units/mL; Sigma Chemical Co., St. Louis, MO) and 0.14% collagenase type I (Sigma).
  • the free cells were decanted through 40-gauge mesh strainers and centrifuged at 200 x g for 10 minutes. The supernatant was removed and viable cells were resuspended in RPMI 1640. The cell number was determined using a hematocytometer and 0.04%) trypan blue dye. The cells were then centrifuged and the pellet resuspended in RPMI 1640 at 5 x l0 5 cells/mL.
  • Human cancer cells were obtained from operative specimens provided by the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, or the Department of Surgical Pathology of Los Angeles County/University of Southern California School of Medicine. Tumor cells were maintained in vitro in RPMI 1640 medium supplemented with
  • streptomycin 100 ⁇ g/mL
  • fungizone (1.25 ⁇ g/mL)
  • AII(l-7) (SEQ ID NO:4) was added to samples as an overlayer in 300 ⁇ L of RPMI-
  • hydro lysates were precipitated by adding 30 ⁇ L of 1% human serum albumin (Sigma)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des méthodes, des composés et des compositions pharmaceutiques visant à inhiber la prolifération des cellules tumorales, par administration à un sujet d'une quantité efficace d'angiotensinogène, d'angiotensine I (AI), d'analogues AI, de fragments AI et d'analogues de ceux-ci, d'angiotensine II (AII), d'analogues AII, de fragments AII ou d'analogues de ceux-ci ou d'agonistes du récepteur AII AT2 de type 2.
PCT/US2002/013502 2001-05-01 2002-04-26 Methodes d'inhibition de la proliferation des cellules tumorales WO2002087504A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002308522A AU2002308522A1 (en) 2001-05-01 2002-04-26 Methods for inhibiting tumor cell proliferation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28776001P 2001-05-01 2001-05-01
US60/287,760 2001-05-01

Publications (2)

Publication Number Publication Date
WO2002087504A2 true WO2002087504A2 (fr) 2002-11-07
WO2002087504A9 WO2002087504A9 (fr) 2009-10-22

Family

ID=23104214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/013502 WO2002087504A2 (fr) 2001-05-01 2002-04-26 Methodes d'inhibition de la proliferation des cellules tumorales

Country Status (3)

Country Link
US (1) US7122523B2 (fr)
AU (1) AU2002308522A1 (fr)
WO (1) WO2002087504A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485116A2 (fr) * 2002-02-27 2004-12-15 Wake Forest University L'angiotensine-(1-7) et agonistes de l'angiotensine-(1-7) pour l'inhibition de la croissance de cellules cancereuses
WO2011009152A1 (fr) 2009-07-23 2011-01-27 Affiris Ag Vaccin
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
WO2013091883A3 (fr) * 2011-12-23 2013-10-24 Medical Research Council Ligands de gpcr sélectifs
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
WO2021023698A1 (fr) 2019-08-02 2021-02-11 Lanthiopep B.V Agonistes du récepteur de l'angiotensine 2 (at2) destinés à être utilisés dans le traitement du cancer

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227507A1 (en) * 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
US20140296143A1 (en) * 2008-06-28 2014-10-02 Wake Forest Innovations Angiotensin-(1-7) As A Chemoprevention Agent
EP2849773A1 (fr) 2012-05-14 2015-03-25 University of Southern California Procédés pour limiter le développement d'une plaie cutanée
CA2902619A1 (fr) 2013-03-15 2014-09-25 University Of Southern California Methodes de traitement de la sclerose en plaques
EP3935944A1 (fr) 2013-03-15 2022-01-12 University Of Southern California, USC Stevens Composés pour le traitement des maladies musculo-squelettiques
JP6254692B2 (ja) 2013-07-03 2017-12-27 ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ 認知機能不全を治療するための方法
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
US9796759B2 (en) 2014-07-21 2017-10-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
EP3350200A4 (fr) 2015-09-18 2019-03-27 Wake Forest University Health Services Analogues d'angiotensine (1-7) et procédés associés

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243064A (en) * 1986-06-27 1993-09-07 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
US5547659A (en) * 1991-05-07 1996-08-20 Richardson-Vicks Inc. Photoprotection compositions
US5676994A (en) * 1994-04-26 1997-10-14 The United States Of America As Represented By The Secretary Of Agriculture Non-separable starch-oil compositions
US5882713A (en) * 1994-04-26 1999-03-16 The United States Of America As Represented By The Secretary Of Agriculture Non-separable compositions of starch and water-immiscible organic materials
US5925364A (en) * 1994-10-07 1999-07-20 L'oreal Cosmetic or dermatological composition comprising an oil-in-water emulsion comprising oily globules with a lamellar liquid crystal coating

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3750653A (en) * 1970-09-08 1973-08-07 School Of Medicine University Irradiators for treating the body
IN166447B (fr) 1985-11-27 1990-05-12 Ethicon Inc
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5015629A (en) * 1989-06-26 1991-05-14 University Of Southern California Tissue repair
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1995008565A1 (fr) 1993-09-24 1995-03-30 The University Of Southern California Utilisation d'analogues d'angiotensine ii pour la reparation tissulaire
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
AU706333B2 (en) 1993-09-24 1999-06-17 University Of Southern California Use of angiotensin III and analogs thereof in tissue repair
US5730968A (en) * 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9600120D0 (sv) 1996-01-15 1996-01-15 Astra Ab Novel medical use
US6110895A (en) 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
AU755225B2 (en) 1997-12-12 2002-12-05 University Of Southern California Wound healing compositions
AU744799B2 (en) * 1998-03-10 2002-03-07 University Of Southern California Improved radiation therapy methods
CA2339330A1 (fr) 1998-08-13 2000-02-24 University Of Southern California Procede pour augmenter le debit sanguin vers le tissu ischemique
WO2003072059A2 (fr) 2002-02-27 2003-09-04 Wake Forest University L'angiotensine-(1-7) et agonistes de l'angiotensine-(1-7) pour l'inhibition de la croissance de cellules cancereuses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243064A (en) * 1986-06-27 1993-09-07 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
US5547659A (en) * 1991-05-07 1996-08-20 Richardson-Vicks Inc. Photoprotection compositions
US5676994A (en) * 1994-04-26 1997-10-14 The United States Of America As Represented By The Secretary Of Agriculture Non-separable starch-oil compositions
US5882713A (en) * 1994-04-26 1999-03-16 The United States Of America As Represented By The Secretary Of Agriculture Non-separable compositions of starch and water-immiscible organic materials
US5925364A (en) * 1994-10-07 1999-07-20 L'oreal Cosmetic or dermatological composition comprising an oil-in-water emulsion comprising oily globules with a lamellar liquid crystal coating

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034781B2 (en) 2002-02-27 2011-10-11 Wake Forest University Health Sciences Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
EP1485116A4 (fr) * 2002-02-27 2006-06-07 Univ Wake Forest L'angiotensine-(1-7) et agonistes de l'angiotensine-(1-7) pour l'inhibition de la croissance de cellules cancereuses
US7375073B2 (en) 2002-02-27 2008-05-20 Wake Forest University Health Sciences Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
EP1485116A2 (fr) * 2002-02-27 2004-12-15 Wake Forest University L'angiotensine-(1-7) et agonistes de l'angiotensine-(1-7) pour l'inhibition de la croissance de cellules cancereuses
US9029327B2 (en) 2009-07-23 2015-05-12 Affiris Ag Vaccine
AT508569A1 (de) * 2009-07-23 2011-02-15 Affiris Ag Pharmaceutical compound
EP2529748A2 (fr) 2009-07-23 2012-12-05 Affiris AG Vaccin
WO2011009152A1 (fr) 2009-07-23 2011-01-27 Affiris Ag Vaccin
WO2013091883A3 (fr) * 2011-12-23 2013-10-24 Medical Research Council Ligands de gpcr sélectifs
CN104040345A (zh) * 2011-12-23 2014-09-10 医疗研究局 血管紧张素ii受体的选择性配体
JP2015509914A (ja) * 2011-12-23 2015-04-02 メディカル リサーチ カウンシル 選択的ｇｐｃｒリガンド
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9511055B2 (en) 2012-10-02 2016-12-06 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
WO2021023698A1 (fr) 2019-08-02 2021-02-11 Lanthiopep B.V Agonistes du récepteur de l'angiotensine 2 (at2) destinés à être utilisés dans le traitement du cancer

Also Published As

Publication number Publication date
AU2002308522A8 (en) 2009-12-03
US20040176302A1 (en) 2004-09-09
WO2002087504A9 (fr) 2009-10-22
US7122523B2 (en) 2006-10-17
AU2002308522A1 (en) 2002-11-11

Similar Documents

Publication Publication Date Title
US7118748B1 (en) Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US7122523B2 (en) Methods for inhibiting tumor cell proliferation
US7786085B2 (en) Method for treating a patient undergoing chemotherapy
EP1158997A2 (fr) Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
US6747008B1 (en) Methods for treating and preventing alopecia
US6762167B1 (en) Methods for treating a patient undergoing chemotherapy
US6821953B1 (en) Methods for treating and preventing damage to mucosal tissue
CA2205092C (fr) Utilisation de fragments d'angiotensine ii et d'analogues de celle-ci pour la reparation des tissus
CA2322963C (fr) Procede d'augmentation du taux de survie des globules blancs apres une chimiotherapie
JPH11507362A (ja) 組織修復におけるアンジオテンシンｉｉ２型受容体アゴニストの使用
WO1999031125A1 (fr) Compositions de cicatrisation
WO1999040106A2 (fr) Procede pour promouvoir l'erythropoiese
US6730775B1 (en) Methods for limiting scar and adhesion formation
CA2367107C (fr) Procede pour limiter la formation de cicatrices et d'adherences
US20020049162A1 (en) Methods for inhibiting smooth muscle cell proliferation
US20020165141A1 (en) Methods for promoting dendritic cell proliferation or differentiation
WO2001044270A2 (fr) Procedes permettant de traiter et d'empecher des complications diabetiques
EP1239867B1 (fr) Procedes permettant de traiter et d'empecher des lesions des muqueuses
EP1292610A1 (fr) Procedes de traitement et de prevention de l'alopecie
CA2442340A1 (fr) Proceder pour limiter la formation de cicatrices et d'adherences
MXPA97009983A (en) The use of receptor agonists type 2 angiothesin ii in the preparation of compositions for the preparation of teji

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP